Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
Just a few quick questions (3!) and you'll zip to the webinar...
MASLD/MASH Webinar Pre-Survey
Which of the following is true about noninvasive testing for MASLD/MASH?
[ Required ]
Noninvasive tests can be used for risk stratification in the diagnostic evaluation of patients with MASLD
A Fibrosis 4 Index score >1.3 indicates the absence of liver fibrosis, so further testing is unnecessary
A Fibrosis 4 Index score <1.3 is associated with strong positive predictive value for advanced hepatic fibrosis
Noninvasive testing is not useful in the diagnostic evaluation for MASLD/MASH, but can help guide treatment
Which of the following pharmacologic treatment options are FDA-approved for treating MASH?
[ Required ]
Pioglitazone
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Metformin
None of the above
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
Submit